O Shaughnessy Asset Management LLC Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

O Shaughnessy Asset Management LLC bought a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the 4th quarter, Holdings Channel reports. The fund bought 8,617 shares of the biopharmaceutical company’s stock, valued at approximately $259,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Blue Trust Inc. increased its position in TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 371 shares during the period. Smartleaf Asset Management LLC increased its position in shares of TG Therapeutics by 512.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 1,594 shares during the period. Jones Financial Companies Lllp raised its stake in TG Therapeutics by 460.7% in the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock worth $64,000 after buying an additional 1,737 shares in the last quarter. Synergy Asset Management LLC purchased a new stake in TG Therapeutics in the fourth quarter worth about $75,000. Finally, GAMMA Investing LLC boosted its position in TG Therapeutics by 562.4% during the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 2,171 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Trading Up 2.0 %

TG Therapeutics stock opened at $36.71 on Friday. TG Therapeutics, Inc. has a 12 month low of $12.93 and a 12 month high of $43.32. The company has a market capitalization of $5.77 billion, a price-to-earnings ratio of -367.06 and a beta of 2.14. The business’s fifty day simple moving average is $35.76 and its two-hundred day simple moving average is $31.39. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. The company had revenue of $108.19 million for the quarter, compared to analysts’ expectations of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. As a group, equities analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.